Clinical Trial Update: Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Switch to Infliximab After Incomplete Response to Etanercept [Phase 3]

View source ↗

Summary

This Phase 3 open-label pilot trial investigates switching rheumatoid arthritis patients who have an incomplete response to etanercept to infliximab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Etanercept (etanercept)
• Infliximab (infliximab)

Snippet

Sponsor: Centocor Ortho Biotech Services, L.L.C. | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED